



## COMPANY OVERVIEW

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immunostimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.

## RECENT NEWS

### [Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018](#)

Aug 13 2018, 7:30 AM EDT

### [Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial](#)

Aug 9 2018, 7:30 AM EDT

### [Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066](#)

Jul 31 2018, 7:30 AM EDT

## STOCK OVERVIEW

Symbol	MBRX
Exchange	Nasdaq
Market Cap	43.52m
Last Price	\$1.62
52-Week Range	\$1.50 - \$3.34

## INVESTOR RELATIONS

Lytham Partners, LLC  
Joe Dorame  
Managing Partner  
T: (602) 889-9700

## MANAGEMENT TEAM

### **Walter V. Klemp**

Founder, President, Chairman, CEO, and Business Advisory Board Member

### **Donald Picker, PhD**

Chief Scientific Officer

### **Robert Shepard, MD, FACP**

Chief Medical Officer - Hematology

### **Sandra Silberman, MD, PhD**

Chief Medical Officer - New Products

### **Jonathan P. Foster**

Chief Financial Officer

## MOLECULIN BIOTECH, INC.

2575 W. Bellfort  
Ste. 333  
Houston, TX 77054  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.